| [1] |
Marko J, Marko KI, Pachigolla SL, et al. Mucinous Neoplasms of the Ovary: Radiologic-Pathologic Correlation[J]. Radiographics, 2019, 39(4):982-997. doi: 10.1148/rg.2019180221.
|
| [2] |
Hasbay E, Görgülü G, Sanci M, et al. Role of magnetic resonance imaging in the differentiation of mucinous ovarian carcinoma and mucinous borderline ovarian tumors[J]. Rev Assoc Med Bras (1992), 2023, 69(7):e20230110. doi: 10.1590/1806-9282.20230110.
|
| [3] |
Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage[J]. J Natl Cancer Inst, 2019, 111(1):60-68. doi: 10.1093/jnci/djy071.
|
| [4] |
Craig O, Salazar C, Gorringe KL. Options for the Treatment of Mucinous Ovarian Carcinoma[J]. Curr Treat Options Oncol, 2021, 22(12):114. doi: 10.1007/s11864-021-00904-6.
|
| [5] |
李方, 刘赛娜, 齐长海, 等. CK7、CK20、Villin、CDX-2、MUC-2、PAX8在卵巢原发性黏液性肿瘤和继发性腹膜假黏液瘤中的表达及鉴别诊断意义[J]. 诊断病理学杂志, 2023, 30(7):643-647. doi: 10.3969/j.issn.1007-8096.2023.07.005.
|
| [6] |
Zhang Y, Li C, Luo S, et al. Retrospective Study of the Epidemiology, Pathology, and Therapeutic Management in Patients With Mucinous Ovarian Tumors[J]. Technol Cancer Res Treat, 2020, 19:1533033820946423. doi: 10.1177/1533033820946423.
|
| [7] |
Lertkhachonsuk AA, Buranawongtrakoon S, Lekskul N, et al. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors[J]. J Obstet Gynaecol Res, 2020, 46(11):2287-2291. doi: 10.1111/jog.14427.
|
| [8] |
Taylor EC, Irshaid L, Mathur M. Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation[J]. Radiographics, 2021, 41(1):289-315. doi: 10.1148/rg.2021200086.
|
| [9] |
Euscher ED. Germ Cell Tumors of the Female Genital Tract[J]. Surg Pathol Clin, 2019, 12(2):621-649. doi: 10.1016/j.path.2019.01.005.
|
| [10] |
Razia S, Nakayama K, Yamashita H, et al. Histological and Genetic Diversity in Ovarian Mucinous Carcinomas: A Pilot Study[J]. Curr Oncol, 2023, 30(4):4052-4059. doi: 10.3390/curroncol30040307.
|
| [11] |
Wang Y, Peng L, Ye W, et al. Multimodal diagnostic strategies and precision medicine in mucinous ovarian carcinoma: a comprehensive approach[J]. Front Oncol, 2024, 14:1391910. doi: 10.3389/fonc.2024.1391910.
|
| [12] |
Simons M, Simmer F, Bulten J, et al. Two types of primary mucinous ovarian tumors can be distinguished based on their origin[J]. Mod Pathol, 2020, 33(4):722-733. doi: 10.1038/s41379-019-0401-y.
|
| [13] |
Cheasley D, Wakefield MJ, Ryland GL, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma[J]. Nat Commun, 2019, 10(1):3935. doi: 10.1038/s41467-019-11862-x.
|
| [14] |
Mills AM, Shanes ED. Mucinous Ovarian Tumors[J]. Surg Pathol Clin, 2019, 12(2):565-585. doi: 10.1016/j.path.2019.01.008.
|
| [15] |
Karpathiou G, Venet M, Mobarki M, et al. FOXA1 is expressed in ovarian mucinous neoplasms[J]. Pathology, 2017, 49(3):271-276. doi: 10.1016/j.pathol.2016.11.009.
|
| [16] |
Nazari F, Dehghani Z. Coexistence of Benign Brenner Tumor with Mucinous Cystadenoma in an Ovarian Mass[J]. Iran J Pathol, 2020, 15(4):334-337. doi: 10.30699/ijp.2020.104017.2052.
|
| [17] |
鲍洢婷, 袁蕾, 张浩. 宫颈微偏腺癌27例临床病理分析[J]. 现代妇产科进展, 2022, 31(11):801-806. doi: 10.13283/j.cnki.xdfckjz.2022.11.001.
|
| [18] |
Ehmann S, Sassine D, Straubhar AM, et al. Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers[J]. Gynecol Oncol, 2022, 167(3):458-466. doi: 10.1016/j.ygyno.2022.10.003.
|
| [19] |
Chui MH, Ellenson LH. Mixed Ovarian Neoplasms With Gastrointestinal-type Mucinous and Mullerian Epithelial Components: A Rare Group of Tumors Demonstrating the Phenotypic Plasticity of the Mullerian Epithelial Cell[J]. Am J Surg Pathol, 2023, 47(7):756-765. doi: 10.1097/PAS.0000000000002045.
|
| [20] |
Caruso G, Weroha SJ, Cliby W. Ovarian Cancer: A Review[J]. JAMA, 2025, 334(14):1278-1291. doi: 10.1001/jama.2025.9495.
|